Intellia Therapeutics Inc. overhyped its lung-disease therapy study despite inefficiencies and costliness of such viral-editing treatments, sending share prices down 15%, a proposed class action says.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Intellia ...

We recently compiled a list of the Cathie Wood’s Stock Portfolio: 2025 Stock Picks. In this article, we are going to take a ...

Inc. ("Intellia Therapeutics, Inc.") (NASDAQ:NTLA) concerning possible violations of federal securities laws. Intellia issued a press release on January 9, 2025, "announc[ing] its strategic ...

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal weight rating in a report published on Monday morning, MarketBeat.com reports.

The complete 8-K filing and updates can be accessed on Intellia Therapeutics’ official website. This news release may contain forward-looking statements subject to risks and uncertainties ...

CAMBRIDGE, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

Intellia Therapeutics (NASDAQ ... Intellia’s 1/9/25 news release disclosed that it ended 2024… with approximately $862 million in cash, cash equivalents and investments. The combination ...